Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746798 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 479
- Enrollment target
NCT00746798 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 479 participants.
The verdict
NCT00746798, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 479 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ChimeriVax-WN02 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00746798
The ClinicalTrials.gov registry entry for NCT00746798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00746798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00746798 about?
NCT00746798 is a clinical study titled "Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults". The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
What is the current status of trial NCT00746798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 479 participants. The study started on 2008-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00746798?
The interventions under investigation include: Placebo (BIOLOGICAL), ChimeriVax-WN02 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00746798?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.